188rhenium-TDD-lipiodol in treatment of inoperable primary hepatocellular carcinoma--a case report.
BACKGROUND
The aim of this study was to investigate the potential of using 188Re Lipiodol for selective internal radiation therapy of inoperable hepatocellular carcinoma (HCC).


METHODS
A 33-year-old female with poorly-differentiated multicentric HCC, elevated alpha-fetoprotein (AFP) and increased serum alkaline phosphatase.


METHODS
Over a 2-month interval, the patient was treated twice with 4GBq of 188Re-TDD-Lipiodol.


RESULTS
There was good localisation of 188Re Lipiodol in the tumours, but also in thyroid (first treatment) and gastrointestinal tract (both treatments). So far (5 months post-treatment), the patient remains well with stable disease.


CONCLUSIONS
188Re Lipiodol can be an effective radiopharmaceutical for the treatment of HCC; however, more work must be done to minimise the uptake in bowel.
Sundram
F X
FX
Department of Nuclear Medicine, Singapore General Hospital, 1 Hospital Drive, Singapore 169608. gnmfxs@sgh.com.sg
Yu
S W
SW
Jeong
J M
JM
Somanesan
S
S
Premaraj
J
J
Saw
M M
MM
Tan
B S
BS
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007459:Iodized Oil; D008113:Liver Neoplasms / Q000532:radiotherapy*; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
C431271:188Re 2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol; D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D007459:Iodized Oil